Publication of the EMSCO EUROPE trial

We are happy to announce that the results of our EUROPE clinical phase 2 study have now been published. The trial results confirm that romiplostim is safe and effective in a large subset of LR-MDS patients. Furthermore, we were able to deduct response prediction based on SRSF2 mutational status, which may allow for better personalized treatment in the future. We would like to thank everyone involved for their continuous support!
read more…

September 28th 2022

CANFIRE trial of the German MDS Study Group open for recruitment

The CANFIRE trial is a phase 2, single-arm, open-label study to assess the efficacy and safety of canakinumab for the treatment of anemia in patients with lower-risk MDS or MDS/MPN. It will enrol up to 50 patients who will be treated for 6 months with the aim to assess HI-E as the primary endpoint.
read more…

July 12th 2022